BME:ALMPharmaceuticals
Assessing Almirall (BME:ALM) Valuation After China Seysara Approval And Sinomune Licensing Deal
What the Seysara approval in China means for Almirall
Almirall (BME:ALM) is back on investors radar after China approved its dermatology focused oral antibiotic Seysara for moderate to severe acne, alongside a new licensing and distribution deal with Sinomune.
See our latest analysis for Almirall.
The Seysara approval appears to have come at a time when momentum has been mixed, with a recent 1 day share price return of 2.77% contrasting with a 30 day share price return decline of 2.17%, while...